Open Orphan (ORPH) Contract signed with Carna Bioscience November 18, 2019 – Posted in: Open Orphan (ORPH)

  Open Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce the signing of a contract with Carna Bioscience (“Carna”) (www.carnabio.com) for a First In Human Clinical pharmacology trial. The contract is expected to deliver significant revenue for the Company over the next twelve  months. Carna is a Japanese company specialising in kinase biology, developing innovative treatments against cancer and immune disorders. This contract sees Venn Life Sciences (“Venn”), part…

Continue reading